Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM)
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Villalba A.
- Gonzalez-Rodriguez A.P.
- Arzuaga-Mendez J.
- Puig N.
- Arguiñano J.M.
- Jimenez M.
- Canet M.
- Teruel A.I.
- Sola M.
- Díaz F.J.
- Encinas C.
- Garcia A.
- Rosiñol L.
- Suárez A.
- Gonzalez M.S.
- Izquierdo I.
- Hernández M.T.
- Infante M.S.
- Sánchez M.J.
- Sampol A.
Grupos
Abstract
Tandem ASCT has been suggested as a valid approach to improve the prognosis of patients with MM and HR cytogenetic. In this observational, retrospective study, 213 patients with newly diagnosed MM and HR cytogenetic in 35 hospitals from the Spanish Myeloma Group underwent single or tandem ASCT between January 2015 and December 2019 after induction with VTD/VRD. HR cytogenetic was defined as having =1 of the following: del17p, t(4;14), t(14;16) or gain 1q21. More patients in the tandem group had R-ISS 3 and >1 cytogenetic abnormality at diagnosis. With a median follow-up of 31 months (range, 10–82), PFS after single ASCT was 41 months versus 48 months with tandem ASCT (p = 0.33). PFS in patients with del17p undergoing single ASCT was 41 months, while 52% of patients undergoing tandem ASCT were alive and disease free at 48 months. In conclusion, tandem ASCT partly overcomes the bad prognosis of HR cytogenetic. © 2022 Informa UK Limited, trading as Taylor & Francis Group.
Datos de la publicación
- ISSN/ISSNe:
- 1042-8194, 1029-2403
- Tipo:
- Article
- Páginas:
- 3438-3447
- PubMed:
- 36124538
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 0,741 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
LEUKEMIA & LYMPHOMA TAYLOR & FRANCIS LTD
Documentos
- No hay documentos
Filiaciones
Keywords
- Cytogenetic Analysis; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Retrospective Studies; Transplantation, Autologous; antibiotic agent; bortezomib; busulfan; carfilzomib; dexamethasone; lenalidomide; melphalan; phenytoin; thalidomide; adult; aged; antibiotic prophylaxis; Article; autologous stem cell transplantation; cancer patient; cancer prognosis; chromosome aberration; cytogenetics; female; follow up; high risk cytogenetics; human; induction chemotherapy; major clinical study; male; mortality; multiple myeloma; myeloma; observational study; open study; overall survival; progression free survival; retrospective study; seizure; single drug dose; transplantation conditioning; treatment response; autotransplantation; chromosome analysis; disease free survival; hematopoietic stem cell transplantation; multiple myeloma
Campos de Estudio
Cita
Villalba A,Gonzalez AP,Arzuaga J,Puig N,ARNAO M,Arguiñano JM,Jimenez M,Canet M,Teruel AI,Sola M,Díaz FJ,Encinas C,Garcia A,Rosiñol L,Suárez A,Gonzalez MS,Izquierdo I,Hernández MT,Infante MS,Sánchez MJ,Sampol A,DE LA RUBIA J. Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM). Leuk. Lymphoma. 2022. 63. (14):p. 3438-3447. IF:2,600. (3).
Portal de investigación